Tectonic Therapeutic financials
$23.34−0.72%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating income | -$24.2M | -$27.3M | -$21.5M | -$21.9M | -$22.3M | -$18.3M | -$14.0M | -$19.6M | -$11.4M |
| Net income | -$22.3M | -$25.2M | -$19.2M | -$19.0M | -$20.0M | -$15.9M | -$12.4M | -$17.7M | -$12.7M |
| Net margin | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.18 | $-1.34 | $-1.03 | $-1.02 | $-1.07 | $-0.93 | $-0.83 | $-1.20 | $-4.34 |
| EBITDA | -$23.9M | -$27.0M | -$21.2M | -$21.5M | -$22.0M | -$17.9M | -$13.5M | -$19.2M | -$11.1M |
| Operating cash flow | -$21.5M | -$18.4M | -$14.5M | -$17.8M | -$14.7M | -$13.1M | -$16.8M | -$19.6M | -$13.4M |
| Free cash flow | -$21.5M | -$18.4M | -$14.5M | -$18.0M | -$14.7M | -$13.1M | -$16.8M | -$19.8M | -$13.4M |
| Diluted shares | 19.0M | 18.8M | 18.7M | 18.7M | 18.7M | 17.2M | 14.9M | 14.7M | 2.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $227.1M | $236.9M | $253.8M | $268.4M | $287.4M | $306.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $186.0K | $282.0K | $387.0K | $513.0K | $637.0K | $758.0K |
| Total assets | $237.0M | $246.6M | $261.0M | $277.0M | $295.3M | $314.8M |
| Total liabilities | $13.2M | $16.2M | $9.7M | $9.5M | $11.5M | $13.8M |
| Shareholders' equity | $223.8M | $230.4M | $251.3M | $267.5M | $283.8M | $301.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology